EXELIXIS INC (EXEL)
US30161Q1040 - Common Stock
Taking everything into account, EXEL scores 7 out of 10 in our fundamental rating. EXEL was compared to 568 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. EXEL is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, EXEL could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year EXEL was profitable.
EXEL had a positive operating cash flow in the past year.
Each year in the past 5 years EXEL has been profitable.
Each year in the past 5 years EXEL had a positive operating cash flow.
1.2 Ratios
EXEL has a Return On Assets of 15.77%. This is amongst the best in the industry. EXEL outperforms 98.23% of its industry peers.
EXEL has a better Return On Equity (20.52%) than 97.35% of its industry peers.
The Return On Invested Capital of EXEL (18.78%) is better than 97.88% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is significantly below the industry average of 13.59%.
The 3 year average ROIC (7.03%) for EXEL is below the current ROIC(18.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.77% | ||
| ROE | 20.52% | ||
| ROIC | 18.78% |
ROA(3y)7.28%
ROA(5y)8.82%
ROE(3y)8.99%
ROE(5y)10.39%
ROIC(3y)7.03%
ROIC(5y)8.48%
1.3 Margins
EXEL has a better Profit Margin (22.43%) than 97.52% of its industry peers.
In the last couple of years the Profit Margin of EXEL has declined.
EXEL has a better Operating Margin (29.22%) than 98.58% of its industry peers.
EXEL's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 96.25%, EXEL belongs to the top of the industry, outperforming 96.64% of the companies in the same industry.
EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.22% | ||
| PM (TTM) | 22.43% | ||
| GM | 96.25% |
OM growth 3Y-5.74%
OM growth 5Y-28.9%
PM growth 3Y0.09%
PM growth 5Y-32.47%
GM growth 3Y-0.1%
GM growth 5Y-0.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), EXEL is creating some value.
Compared to 1 year ago, EXEL has less shares outstanding
The number of shares outstanding for EXEL has been increased compared to 5 years ago.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 10.49 indicates that EXEL is not in any danger for bankruptcy at the moment.
EXEL's Altman-Z score of 10.49 is amongst the best of the industry. EXEL outperforms 86.55% of its industry peers.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 10.49 |
ROIC/WACC1.59
WACC11.78%
2.3 Liquidity
A Current Ratio of 3.93 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Current ratio of 3.93. This is comparable to the rest of the industry: EXEL outperforms 46.37% of its industry peers.
EXEL has a Quick Ratio of 3.88. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.88, EXEL is in line with its industry, outperforming 47.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.88 |
3. Growth
3.1 Past
EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 485.71%, which is quite impressive.
The earnings per share for EXEL have been decreasing by -14.85% on average. This is quite bad
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.31%.
EXEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.47% yearly.
EPS 1Y (TTM)485.71%
EPS 3Y22.28%
EPS 5Y-14.85%
EPS Q2Q%N/A
Revenue 1Y (TTM)17.31%
Revenue growth 3Y22.83%
Revenue growth 5Y16.47%
Sales Q2Q%14.33%
3.2 Future
Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 40.97% on average per year.
Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 10.44% on average per year.
EPS Next Y171.3%
EPS Next 2Y64.39%
EPS Next 3Y52.07%
EPS Next 5Y40.97%
Revenue Next Year18.02%
Revenue Next 2Y9.45%
Revenue Next 3Y10.03%
Revenue Next 5Y10.44%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.15 indicates a rather expensive valuation of EXEL.
Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.22% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of EXEL to the average of the S&P500 Index (28.77), we can say EXEL is valued slightly cheaper.
The Price/Forward Earnings ratio is 20.06, which indicates a rather expensive current valuation of EXEL.
EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 95.04% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.38, EXEL is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.15 | ||
| Fwd PE | 20.06 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaper than 96.99% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, EXEL is valued cheaply inside the industry as 96.11% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.9 | ||
| EV/EBITDA | 12.24 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 52.07% in the coming years.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y64.39%
EPS Next 3Y52.07%
5. Dividend
5.1 Amount
EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EXELIXIS INC
NASDAQ:EXEL (12/17/2024, 8:56:25 PM)
After market: 34.69 0 (0%)34.69
-1.38 (-3.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.91B
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.15 | ||
| Fwd PE | 20.06 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.12
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.77% | ||
| ROE | 20.52% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 29.22% | ||
| PM (TTM) | 22.43% | ||
| GM | 96.25% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.93 | ||
| Quick Ratio | 3.88 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)485.71%
EPS 3Y22.28%
EPS 5Y
EPS Q2Q%
EPS Next Y171.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)17.31%
Revenue growth 3Y22.83%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y